Skip to main
VNDA

Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target

Vanda Pharmaceuticals (VNDA) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Vanda Pharmaceuticals is witnessing strong growth in its product portfolio, particularly with Ponvory experiencing record new patient prescriptions following its launch, indicating robust underlying demand that is expected to translate into significant gross sales of $172.8 million by 2034. Fanapt also showed impressive performance, with revenue growth of 27% in 2Q25 and 31% in 3Q25, suggesting an annualized run-rate nearing $120 million, alongside a marked increase in new prescriptions. The ongoing investments in prescriber awareness and the anticipated impact of bipolar approval on Fanapt's sales momentum reinforce a positive outlook for the company's commercial strategy and revenue potential.

Bears say

Vanda Pharmaceuticals Inc. reported net product sales of $7.1 million in 2Q25, which marked an 18% year-over-year decline, and faced significant disruption from recent changes in distribution and pricing structures following its December 2024 acquisition. The company anticipates a rapid erosion of exclusivity by the end of 2027 for key products like Fanapt, exacerbated by competition from generics and transitioning patient preferences towards alternatives with better reimbursement terms. Additionally, Vanda's commercial traction is hindered by challenges in the flare segment and risks related to regulatory setbacks and potential dilution from future acquisitions, all contributing to a negative outlook on the stock.

Vanda Pharmaceuticals (VNDA) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vanda Pharmaceuticals (VNDA) Forecast

Analysts have given Vanda Pharmaceuticals (VNDA) a Buy based on their latest research and market trends.

According to 4 analysts, Vanda Pharmaceuticals (VNDA) has a Buy consensus rating as of Feb 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vanda Pharmaceuticals (VNDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.